WILEX

Focused Cancer Therapies

9-MONTH FINANCIAL REPORT 2010

Highlights Q3:

- ➜ Mandatory offer from dievini Hopp BioTech closed
- ➜ Rights issue successfully executed
- ➜ GMP certification renewed
- ➜ Financials in line with expectations

Key figures

	9M 2010 [1] € '000	9M 2009 [1] € '000	Change in %
Earnings			
Sales revenue	0	5,000	n/a
Other income	1,244	1,925	(35.4)
Operating expenses	(18,479)	(18,118)	2.0
of which research and development costs	(15,095)	(15,162)	(0.4)
Operating result	(17,235)	(11,193)	54.0
Earnings before tax	(17,217)	(11,049)	55.8
Net loss for the period	(17,222)	(11,059)	55.7
Earnings per share in €	(1.06)	(0.84)	27.1
Balance sheet as of end of period			
Total assets	10,994	12,328	(10.8)
Cash and cash equivalents	7,762	8,931	(13.1)
Equity	4,530	4,690	(3.4)
Equity ratio [2] in %	41.2	38.0	8.3
Cash flow statement			
Cash flow from operating activities	(13,952)	(13,178)	5.9
Cash flow from investing activities	(11)	(61)	(82.6)
Cash flow from financing activities	18,296	9,844	85.8
Employees (number)			
Employees as of end of period [3]	72	67	7.5
Employees – average for the reporting period [3]	72	68	5.9

[1] The reporting period begins on 1 December and ends on 31 August.

[2] equity/total assets

[3] including members of the Executive Management Board

Rounding of exact figures may result in differences.

Letter to the Shareholders

Dear Shareholders,

As we reported to you in July, the first half of the year was both successful and eventful in terms of our clinical activities whilst the third quarter was marked mainly by a takeover offer and a capital increase.

In July, we announced that our main shareholder, dievini Hopp BioTech, had become obliged to submit a takeover offer for the Company's shares after passing the 30 % share-holding threshold. Following publication of the offer document in July, the Executive Management Board and Supervisory Board issued a joint statement recommending shareholders to reject the offer. This recommendation to WILEX AG's shareholders was based on management's assessment that, although the offer price of € 4.10 per WILEX share was slightly above the minimum offer prescribed by law, it failed to reflect the Company's true potential. A total of 22,953 shares (0.12 % of the share capital) were transferred to dievini Hopp Biotech before the mandatory offer closed in August.

We thank you for the trust that you placed in us in connection with the rights issue in August. It was not just the subscription ratio of 72 % that was very positive but also the large demand for additional subscriptions to shares. Due to this high level of over-subscription, each over-subscription right placed resulted in an allocation ratio of approximately 21 %. The net proceeds of the issue, amounting to approx. € 10 million, will be used to fund our ongoing clinical trials.

The clinical development of our product candidates continues on track and as planned. We are approaching the next milestone in the RENCAREX® ARISER trial and have made good progress in patient recruitment for the MESUPRON® breast cancer trial. We are currently preparing all documents, reports and analyses necessary for filing the US drug approval application related to our diagnostic candidate REDECTANE® in the kidney tumour indication based on the positive data from the candidate's Phase III registration trial. This is being done in close collaboration with the US Food and Drug Administration (FDA).

We are pleased that, following a comprehensive inspection by the responsible German authorities (Government of Upper Bavaria), our manufacturing site has been re-certified as being in compliance with the standards and guidelines of Good Manufacturing Practice (GMP). This means that we have met another key requirement for marketing WILEX's product candidates.

Management focus in the coming months will be on activities related to the commercialisation of our product candidates, as well as securing the Company's finances in the medium and long term.

The next few months promise to be very interesting. We hope that you will continue to accompany us on our path.

Munich, 13 October 2010

Peter Llewellyn-Davies
Chief Financial Officer

Interim management report for the period from 1 December 2009 to 31 August 2010

Research and development

WILEX is a biopharmaceutical company that is focused on oncology and develops drugs with a low side-effect profile for the targeted treatment of different types of cancer as well as diagnostic agents for the specific detection of these diseases. The Company's product candidates are based on antibodies and small molecules aimed at inhibiting tumour growth and preventing metastases. For a detailed description of the Company's business activities, please see the most recent annual report.

REDECTANE®

WILEX announced the final data of the Phase III registration trial of its diagnostic candidate REDECTANE® (INN: Iodine (^{124}I) Girentuximab) in the second quarter of 2010. The REDECT trial has shown that combining REDECTANE® with positron emission tomography (PET) and computer tomography (CT) is clearly superior to the use of CT alone in diagnosing clear cell renal cell carcinomas. In the trial, 226 patients were examined with PET/CT and REDECTANE® as well as with a diagnostic CT prior to kidney surgery. Subsequently, histological examinations of the surgically removed tissue samples were performed in order to verify the analyses by the radiologists and the nuclear medicine specialists. WILEX is currently preparing an application for approval (Biological License Application, BLA) with the FDA whilst working at the same time with our marketing partner, Ion Beam Applications S.A., Brussels, Belgium (IBA), on pre-marketing activities in the United States.

RENCAREX®

The Phase III ARISER trial of RENCAREX® (INN: Girentuximab) included 864 patients who had either the whole kidney or the diseased part of the kidney removed and who had no detectable metastases after surgery. These patients were randomly divided into two groups and administered either RENCAREX® or a placebo. This double-blind trial will have achieved its endpoint when disease-free survival of patients in the group treated with RENCAREX® shows a statistically significant improvement compared to the placebo group. The next milestone pursuant to the study protocol is the occurrence of the 343rd relapse, which constitutes the basis for the interim analysis for efficacy. As of the end of September 2010, a total of 335 relapses were reported to WILEX by the local trial centres.

MESUPRON®

The small-molecule product candidate MESUPRON® was examined in 95 patients with locally advanced, inoperable, non-metastatic pancreatic cancer. The final data from this Phase II trial of the uPA inhibitor were published in June 2010 and met with a very positive response. This randomised, open, three-arm proof-of-concept trial studied the activity of MESUPRON® given orally once a day in combination with the chemotherapeutic agent Gemcitabine compared with Gemcitabine alone. The therapy proved to be safe and well tolerated. The tumour response rate, one-year survival and median survival of patients treated with MESUPRON® all showed an impressive improvement. The data were presented in October 2010 at the 35th ESMO Conference of the European Society of Medical Oncology in Milan, Italy.

MESUPRON® is currently also being tested in a Phase II trial in patients with metastatic HER2 receptor negative breast cancer. MESUPRON® inhibits the urokinase-specific plasminogen activator (uPA) system, which is believed to play an important role in cancer cell metastasis. This randomised double-blind trial is designed to examine the efficacy of MESUPRON® in combination with the chemotherapeutic agent Capecitabine compared to Capecitabine alone. Patients receive the study medication as first-line treatment after diagnosis of metastases. Of the planned 114 patients a total of 103 patients had been recruited in 21 trial centres in Europe, the USA and Brazil by the end of September 2010. The primary endpoint of the trial is progression-free survival.

WX-554 – MEK inhibitor

WILEX acquired the mitogen-activated protein kinase (MEK) inhibitor WX-554 as a preclinical project from UCB Pharma S.A., Brussels, Belgium (UCB). MEK has been shown to play a central role in signal transduction and is linked to a multitude of biological processes such as cell division, cell differentiation and cell death. The MEK signalling pathway is overexpressed in more than 30 % of cancers, resulting in uncontrolled cell growth and proliferation. The first Phase I trial commenced in late 2009 and the trial data were announced in June 2010. This dose escalation trial aimed to determine safety, tolerability and the optimal biological dose for inhibition of the MEK system by WX-554. The study, which was conducted in Germany, tested five increasing dose levels, each administered once by a 15-minute infusion of WX-554 in five healthy male volunteers. In addition to safety and tolerance, the pharmacokinetic and pharmacodynamic properties of the MEK inhibitor were also investigated. The substance was safe and well tolerated in the 25 healthy volunteers. The MEK signal transduction pathway was inhibited in a dose-dependent manner reaching complete inhibition at 1 mg / kg WX-554.

Preclinical programmes and research

Preclinical trials are being carried out in connection with the orally administered PI3K inhibitor WX-037, which WILEX also took over from UCB. The phosphatidylinositol-3-kinase/protein kinase (PI3K) signalling pathway sends a “growth” signal to the nucleus of a tumour cell and is mutated in many types of cancer. The antibody-based projects acquired from UCB are currently in the research and validation phase.

Market environment

WILEX believes that the market environment for antibodies and small molecules has not changed significantly compared to the disclosures made in the 2009 annual financial statements. For more detailed information, please see pages 34 and 35 of the Annual Report 2009.

Earnings, financial position and net assets

WILEX posted earnings before taxes of € – 17.22 million (previous year: € – 11.05 million) in the first nine months of the 2010 financial year (1 December 2009 to 31 August 2010). At € 17.22 million, the net loss for the period was 55.7 % above the previous year’s figure (€ 11.06 million). Earnings per share decreased to € – 1.06 (previous year: € –0.84).

Sales revenue and other income

WILEX did not recognise any sales revenue in the first nine months of 2010 (previous year: €5.00 million).

At € 1.24 million, other income fell 35.4% compared to the previous year (€ 1.92 million). Income from the US Department of Defense grants for the uPA programme in the amount of €0.40 million (previous year: €0.27 million) increased year on year due to the project's degree of completion. Income realised from the licence agreements with Esteve and IBA was €0.84 million (previous year: € 1.50 million), mainly impacted by the REDECT trial. Income from the reversal of other provisions declined to €0.01 million year on year (previous year: €0.15 million). Prepayments received for research projects are accrued and recognised as other income in line with project costs (percentage-of-completion method).

Other income in € million*



Operating expenses

Operating expenses including depreciation, amortisation and impairment losses amounted to € 18.48 million, up almost 2.0% from the previous year (€ 18.12 million).

Operating expenses in € million*



Research and development costs were € 15.09 million, corresponding to 81.7% of operating expenses. They were 0.4% lower year on year (previous year: € 15.16 million). The ongoing clinical development of the monoclonal antibody Girentuximab for RENCAREX® and REDECTANE® accounted for 47.6% of the research and development costs but was lower year on year (previous year: 69.2%) due to the project's degree of completion. The uPA programme involving the small-molecule drug candidate MESUPRON® accounted for approximately 35.1% (previous year: 19.5%). The planned increase is due to the expenditures for the breast cancer trial given the progress made in patient recruitment. The other projects, which mainly comprise the programmes acquired from UCB, account for 17.3% of our research and development costs. The costs of the WX-554 Phase I trial, preclinical work on WX-037 and research on antibodies were higher year on year (11.3%).

Administrative costs were € 3.38 million, up 14.5 % from the previous year (€ 2.96 million). The increase is due to the first-quarter rise in staff costs which was triggered by the revaluation of the stock options and to consultancy costs incurred as part of the takeover offer, amongst others.

Financing and liquidity

Finance income fell to € 21 k in the reporting period (previous year: € 150 k) due to the use of cash as planned and lower interest rates. The Company exclusively used short-term deposits for investing its liquid funds (e. g. overnight money). Finance costs comprising interest expense and the interest element of liabilities were approximately € 3 k (previous year: € 6 k). The financial result thus fell from € 144 k the previous year to € 18 k this year.

The Company carried out a rights issue in the third quarter during which all 2,455,070 new no par value bearer shares were subscribed at the subscription price of € 4.10 per share in accordance with subscription and oversubscription rights. Following the entry of the capital measure in the Commercial Register on 5 August 2010, the total number of WILEX shares issued increased to 18,413,035. Shareholders exercised subscription rights for a total of 1,766,498 new shares, which corresponds to a subscription ratio of approximately 72 %. A total of 688,572 shares were available under shareholders' oversubscription rights. The shareholders had registered their demand for an additional 3,275,479 shares at the subscription price. The capital increase was therefore substantially oversubscribed and fulfilled based on an allocation quota of about 21 %. WILEX AG plans to use the net proceeds of approximately € 10 million from the rights issue to finance its ongoing clinical studies and continued growth as well as to enhance its equity.

At the end of the third quarter of 2010, the Company had cash and cash equivalents of € 7.76 million (30 November 2009: € 3.41 million; 31 August 2009: € 8.93 million).

Cash flow statement

The net cash flow from operating activities during the reporting period was € – 13.93 million (previous year: € – 12.99 million). At € 10.65 k, the net cash used in investing activities was insignificant (previous year: € 61.33 k). The net cash flow from financing activities in the first nine months was € 18.30 million (previous year: € 9.84 million) and was generated by the cash capital increases executed in the first and third quarter. Total net inflow of cash and cash equivalents was € 4.35 million (previous year: outflow of € 3.21 million). Adjusted for the effects of both the cash capital increase and the milestone payment in the first quarter, WILEX's average use of cash per month in the reporting period was € 2.11 million (previous year: € 2.01 million).

Cash flow 9M 2010 in € million*



Assets

Total assets as of 31 August 2010 amounted to € 10.99 million (30 November 2009: € 12.01 million).

Balance sheet structure – assets in € million*



At € 9.08 million, current assets at the end of the reporting period were lower than at the close of the 2009 financial year (€ 10.13 million).

Non-current assets as of 31 August 2010 amounted to € 1.91 million (30 November 2009: € 1.88 million). Intangible assets essentially comprise licence fees and royalties from various cooperation agreements. At € 1.20 million, these were slightly lower than on 30 November 2009 (€ 1.29 million). Property, plant and equipment amounting to € 0.55 million (30 November 2009: € 0.42 million) primarily concerns laboratory and office equipment. The increase stems from a new leasing contract related to the purchase of one item of laboratory equipment.

Equity

Equity as of the end of the reporting period was € 4.53 million (30 November 2009: € 3.04 million). The two capital measures carried out in the 2010 financial year had a substantial impact on the development of equity compared to the close of the 2009 financial year. New no par value bearer shares were issued in connection with the cash capital increase from authorised capital that was carried out in the third quarter of the financial year to raise the Company's share capital by € 2,455,070.00 to € 18,413,035.00. The changes in equity are explained in more detail in the notes on page 13.

Balance sheet structure – equity and liabilities in € million*



Liabilities

Non-current liabilities fell by 38.0% to €0.38 million, down from €0.62 million as of 30 November 2009. Lease liabilities in the amount of €0.10 million, which did not exist in the previous year, have been recognised since the second quarter of 2010. Other non-current liabilities of €0.26 million as of 31 August 2010 (30 November 2009: €0.59 million) comprised the accrual related to payments from the US Department of Defense over a period of more than one year, the accrual for rented offices as well as the liability for employment anniversaries.

Non-current liabilities decreased to €6.08 million as of the end of the period (30 November 2009: €8.35 million). Other current liabilities fell to €4.09 million (30 November 2009: €6.25 million) due to the progress of the Phase III trials and the fact that the accruals related to the payments from Esteve and IBA were recognised as income. Trade payables amounted to € 1.93 million (30 November 2009: €2.10 million).

Other current liabilities in € million*



Employees and stock options

At the end of the reporting period, 72 employees (30 November 2009: 71; 31 August 2009: 67), including Executive Management Board members, were employed by WILEX. The Company has a performance-related compensation system for its employees. In addition, a stock option plan enables employees and Executive Management Board members to participate in the Company's success. In the first nine months of the financial year, no subscription rights were issued to employees and members of the Executive Management Board. WILEX has issued a total of 1,076,424 subscription rights to employees and members of the Executive Management Board, of which 901,734 options were outstanding at the end of the reporting period. A total of 387,423 subscription rights were available for issuance to employees and to members of the Executive Management Board on 31 August 2010. No stock options were exercised to date.

Report on risks and opportunities

The risks and opportunities that arise in connection with WILEX's business are described in detail on pages 42 to 47 of the Annual Report 2009. We refer particularly to the financing risks and going concern risks described therein. WILEX uses an IT-based risk management system that complies with the requirements of the German Control and Transparency in Business Act (Gesetz zur Kontrolle und Transparenz im Unternehmensbereich) to monitor 16 different risk areas.

WILEX is exposed to risks typical for the industry, namely those arising from the development and production of drug candidates used in cancer therapies. The time between commencement of drug development and approval usually spans many years. Even though our portfolio has matured further, there is a continuing risk that none of our current drug and diagnostic candidates will receive marketing approval.

Events after the reporting period

Following an inspection by the Central Drug Monitoring Office of the government of Upper Bavaria, WILEX was re-certified in September 2010 as being in compliance with the principles and guidelines of Good Manufacturing Practice (GMP). At the same time, the manufacturing and import authorisation pursuant to section 13 and section 72 Arzneimittelgesetz (German Drug Act – AMG) for the production, testing and release of investigational medicinal products for clinical trials and drugs was updated. The comprehensive GMP inspection at WILEX had been conducted in July 2010. The GMP certificate is an important prerequisite for marketing all of WILEX's product candidates.

Outlook

We are currently in talks with the FDA with respect to our diagnostic candidate REDECTANE®, and the BLA is being prepared. At the same time, we are carrying out pre-marketing activities in the United States jointly with our marketing partner, IBA.

WILEX expects the 343rd relapse in the RENCAREX® Phase III ARISER trial – i. e. the next milestone according to the study protocol – to occur by the end of the year. Once the 343rd relapse has occurred, all available data from the 864 patients will be collected and the independent centralised evaluations of all patients' radiological scans performed. Subsequently, an independent interim analysis of efficacy of RENCAREX® will be initiated and conducted by the Independent Data Monitoring Committee (IDMC). This analysis will provide critical information regarding the trial endpoint – disease-free survival – which could form the basis for the European application for marketing approval.

Patient recruitment in the MESUPRON® Phase II trial in the breast cancer indication is likely to be completed by the first quarter of 2011. WILEX expects the data from this study to be available in 2012, given the trial endpoint – progression-free survival.

The activities related to the commercialisation of our product candidates, as well as the Company's funding in the medium and long term, will be at the forefront of the management's activities in the coming months.

Income statement

of WILEX AG in accordance with IFRS for the period from 1 December 2009 to 31 August 2010

	9M 2010 €	9M 2009 €	Q3 2010 €	Q3 2009 €
Sales revenue	0	5,000,000	0	5,000,000
Other income	1,243,624	1,924,790	331,145	786,550
Income	**1,243,624**	**6,924,790**	**331,145**	**5,786,550**
Research and development costs	(15,094,694)	(15,161,521)	(4,900,057)	(5,483,408)
Administrative costs	(3,384,139)	(2,956,387)	(1,101,347)	(933,364)
Operating expenses	**(18,478,833)**	**(18,117,908)**	**(6,001,404)**	**(6,416,772)**
Operating result	**(17,235,209)**	**(11,193,118)**	**(5,670,259)**	**(630,222)**
Finance income	21,184	150,499	4,263	9,599
Finance costs	(3,034)	(6,230)	530	1,746
Financial result	**18,150**	**144,270**	**4,792**	**11,346**
Earnings before tax	**(17,217,059)**	**(11,048,848)**	**(5,665,467)**	**(618,876)**
Income tax	(5,311)	(10,559)	(944)	(3,381)
Net loss for the period	**(17,222,370)**	**(11,059,407)**	**(5,666,411)**	**(622,257)**
Earnings per share				
Basic and diluted earnings per share	(1.06)	(0.84)	(0.34)	(0.05)
Average number of shares issued	16,176,052	13,203,629	16,678,475	13,780,935

Rounding of exact figures may result in differences.

Quarterly comparison

of WILEX AG in accordance with IFRS

	Q3 2010 € '000	Q2 2010 € '000	Q1 2010 € '000	Q4 2009 € '000	Q3 2009 € '000
Sales revenue	0	0	0	5,000	5,000
Other income	331	349	564	1,089	787
Operating expenses	(6,001)	(6,508)	(5,969)	(7,760)	(6,417)
of which research and development costs	(4,900)	(5,418)	(4,777)	(6,661)	(5,483)
Operating result	(5,670)	(6,160)	(5,405)	(1,671)	(630)
Earnings before tax	(5,665)	(6,157)	(5,394)	(1,665)	(619)
Net loss for the period	**(5,666)**	**(6,156)**	**(5,400)**	**(1,670)**	**(622)**
Basic and diluted earnings per share in €	(0.34)	(0.39)	(0.34)	(0.12)	(0.05)
Average number of shares issued in million	16.68	15.96	15.89	13.78	13.78

Rounding of exact figures may result in differences.

Balance sheet

of WILEX AG in accordance with IFRS as of 31 August 2010 and as of 30 November 2009

Assets	31.08.2010 €	30.11.2009 €
Property, plant and equipment	551,622	424,080
Intangible assets	1,197,398	1,293,821
Other non-current assets	161,612	160,715
Non-current assets	**1,910,633**	**1,878,617**
Inventories	34,100	34,100
Other assets and prepayments	1,198,480	1,348,781
Trade receivables	0	5,017,864
Other receivables	88,835	322,260
Cash and cash equivalents	7,762,207	3,411,063
Current assets	**9,083,622**	**10,134,069**
Total assets	**10,994,254**	**12,012,686**

Equity and liabilities	31.08.2010 €	30.11.2009 €
Subscribed capital	18,413,035	13,780,935
Capital reserve	127,443,362	113,367,618
Accumulated losses	(141,326,086)	(124,103,716)
Equity	**4,530,311**	**3,044,837**
Pension provisions	24,163	23,533
Liabilities arising from leases	96,288	0
Other non-current liabilities	261,528	592,997
Non-current liabilities	**381,979**	**616,530**
Trade payables	1,929,795	2,099,138
Liabilities arising from leases	57,773	0
Other current liabilities	4,094,397	6,252,181
Current liabilities	**6,081,964**	**8,351,318**
Total equity and liabilities	**10,994,254**	**12,012,686**

Rounding of exact figures may result in differences.

Cash flow statement

of WILEX AG in accordance with IFRS for the period from 1 December 2009 to 31 August 2010

	9M 2010 €	9M 2009 €
Net loss for the period	**(17,222,370)**	**(11,059,407)**
Adjustment for income statement items		
Measurement of stock options	428,969	100,276
Depreciation/amortisation	157,194	172,969
Increase in pension obligations	630	585
Finance costs	3,034	6,230
Finance income	(21,184)	(150,499)
Tax expense	5,311	10,559
	573,954	**140,120**
Changes in net working capital		
Trade receivables	5,017,864	41,912
Other receivables	233,425	26,134
Prepayments	150,302	(389,632)
Other non-current assets	(897)	(585)
Trade payables	(169,343)	124,365
Other liabilities	(2,534,753)	(2,061,112)
	2,696,598	**(2,258,919)**
Cash flow from operating activities	**(13,951,818)**	**(13,178,206)**
Finance costs paid	(3,255)	(119)
Finance income received	21,184	189,029
Net cash flow from operating activities	**(13,933,889)**	**(12,989,296)**
Cash flow from investing activities		
Purchase of property, plant and equipment	(6,646)	(56,793)
Purchase of intangible assets	(4,002)	(4,534)
Net cash flow from investing activities	**(10,648)**	**(61,327)**
Cash flow from financing activities		
Proceeds from capital increase	18,991,610	10,000,000
Capital increase costs	(672,325)	(140,198)
Repayment finance leases	(23,605)	(15,357)
Net cash flow from financing activities	**18,295,680**	**9,844,445**
Net change in cash and cash equivalents	**4,351,143**	**(3,206,178)**
Cash and cash equivalents		
at beginning of period	3,411,063	12,136,987
at end of period	7,762,207	8,930,809

Rounding of exact figures may result in differences.

Statement of changes in equity

of WILEX AG in accordance with IFRS for the period from 1 December 2009 to 31 August 2010

			Capital reserve			
	Shares	Subscribed capital €	Capital measures/ premium €	Measurement of stock options €	Accumulated losses €	Total €
			103,131,052	2,070,200		
As of 1 December 2008	**11,962,754**	**11,962,754**	**105,201,252**		**(111,374,454)**	**5,789,552**
Measurement of stock options				100,276		100,276
Net loss for the period					(11,059,407)	(11,059,407)
Capital increase after accounting for capital procurement costs	1,818,181	1,818,181	8,041,621			9,859,802
Net change in equity						**(1,099,328)**
			111,172,673	2,170,476		
As of 31 August 2009	**13,780,935**	**13,780,935**	**113,343,149**		**(122,433,861)**	**4,690,224**
			111,172,673	2,194,945		
As of 1 December 2009	**13,780,935**	**13,780,935**	**113,367,618**		**(124,103,716)**	**3,044,837**
Measurement of stock options				428,969		428,969
Net loss for the period					(17,222,370)	(17,222,370)
Capital increase after accounting for capital procurement costs	4,632,100	4,632,100	13,646,775			18,278,875
Net change in equity						**(1,485,474)**
			124,819,448	2,623,914		
As of 31 August 2010	**18,413,035**	**18,413,035**	**127,443,362**		**(141,326,086)**	**4,530,311**

Rounding of exact figures may result in differences.

Responsibility statement of the Executive Management Board

"To the best of our knowledge, and in accordance with the applicable reporting principles, the financial statements for the first nine months give a true and fair view of the assets, liabilities, financial position and profit or loss of WILEX AG, and the interim management report includes a fair review of the development and performance of the business and the position of WILEX AG, together with a description of the material opportunities and risks associated with the expected development of WILEX AG."

Munich, 13 October 2010

Executive Management Board

Professor Olaf G. Wilhelm | Peter Llewellyn-Davies | Dr Paul Bevan | Dr Thomas Borcholte

Selected notes

General

The interim financial statements reproduced in this report were prepared in accordance with the International Financial Reporting Standards (IFRS), IAS 34 "Interim Financial Reporting" issued by the International Accounting Standards Board (IASB) and in compliance with the Interpretations of the Standing Interpretations Committee (SIC) and the International Financial Reporting Interpretations Committee (IFRIC) as well as in accordance with the IFRS recognised by the European Union. These interim financial statements must be read in the context of the annual financial statements as of 30 November 2009 published by the Company for the 2009 financial year.

The Company's assets, liabilities and financial position as well as individual items of the financial statements for the first nine months are explained in detail in the interim management report.

As the business activities do not differ significantly in their risk/reward profiles, WILEX operates in one segment only and therefore does not prepare segment reporting. The Company's business activities are not subject to seasonal influences.

The interim financial statements were not subjected to a review. Pursuant to our Declaration of Compliance from 18 February 2010 with Section 7.1.2 of the German Corporate Governance Code, both the interim financial statements and the management report were discussed with the Supervisory Board's Audit Committee before being published. The 9-month financial report was approved for publication by the Executive Management Board on 13 October 2010.

These interim financial statements as of 31 August 2010 were prepared in accordance with the same accounting policies as the annual financial statements as of 30 November 2009.

Change in equity

Equity as of the end of the reporting period was € 4.53 million (30 November 2009: € 3.04 million). The subscribed capital amounted to € 18.41 million compared to € 13.78 million as of 30 November 2009. The capital reserve was € 127.44 million (30 November 2009: € 113.37 million) and the losses accumulated since the Company's foundation totalled € 141.33 million (30 November 2009: € 124.10 million). The equity ratio was 41.2 % as of 31 August 2010 (30 November 2009: 25.3 %; 31 August 2009: 38.0 %).

Increased expense from the measurement of stock options

The capital measure that was carried out in the first quarter of 2010 resulted in higher expenditure from the measurement of stock options, which is also reflected in the half-yearly financial statements. If the Company increases its share capital by issuing new shares in connection with a capital increase subject to shareholders' subscription right and if the subscription price per share is lower than the exercise price fixed in the option offer, under Article 7 para. 1 of the option terms the exercise price shall be reduced by the difference. Given that no stock options had been exercised under Tranches 1 through 7 by the time the exercise price was repriced, said repricing affected all stock options under these tranches that have not yet expired. All aspects and model parameters were explained in detail on pages 14 and 15 of the 3-month financial report.

WILEX incurred the following costs under the stock option plan as of the reporting date, taking the repricing of the exercise price into account:

	9M 2010 € '000	9M 2009 € '000
Expenses from equity-based compensation transactions	429	100

Related party transactions

The following reportable purchases were made by members of the Supervisory Board during the 2010 reporting period:

Name	Date	Trans-action	Market-place	Price €	Number	Volume €
Andreas R. Krebs	06.08.2010	Purchase	Frankfurt	4.60	18,338	84,354.80
Dr Georg Baur	05.08.2010	Purchase	XETRA	4.59	30,000	138,983.45
Dr Georg Baur	05.08.2010	Purchase	OTC	4.10	25,750	105,575.00
Andreas R. Krebs	05.08.2010	Purchase	OTC	4.10	10,662	43,714.20
Professor Friedrich von Bohlen und Halbach and Professor Christof Hettich [1]	30.07.2010	Purchase	OTC	4.10	875,338	3,588,885.80
Andreas R. Krebs	20.07.2010	Purchase	Frankfurt	4.92	1,000	4,920.40
Professor Friedrich von Bohlen und Halbach and Professor Christof Hettich [1]	28.05.2010	Purchase	OTC	3.90	704,966	2,749,367.40
Professor Friedrich von Bohlen und Halbach and Professor Christof Hettich [1]	27.05.2010	Purchase	OTC	3.90	356,923	1,391,999.70
Professor Friedrich von Bohlen und Halbach [1]	07.12.2009	Purchase	OTC	4.10	362,869	1,487,762.90
Professor Friedrich von Bohlen und Halbach [1]	08.12.2009	Loan of securities [2]	OTC	30,000	944,449	30,000.00

[1] Professor Friedrich von Bohlen und Halbach and Professor Christof Hettich did not carry out transactions of their own but acted indirectly in their capacity as Managing Directors of dievini Verwaltungs GmbH, which is the general partner of dievini Biotech holding GmbH und Co. KG.

[2] The loan of securities was a technical transaction that must be disclosed in connection with the capital increase but did not change the number of shares overall.

No other relationships to related parties exist.

WILEX's shares

Performance of the WILEX share, indexed as of 1 January 2010



WILEX's share started the year at €3.65 and closed the third quarter on 30 September 2010 at €4.69, posting a gain of 28%. While the DAXsubsector Biotechnology Index gained just under 5% compared to the start of the year, the NASDAQ Biotechnology Index lost 12% of its value during the year's first nine months. The rapid rise in the Company's share price in late May was triggered by the positive data related to the REDECTANE® and MESUPRON® trials, as well as the fact that dievini Hopp BioTech and UCB fully took over APAX's equity interest in WILEX. The announcement of both the offer price of €4.10 per share for dievini Hopp BioTech's mandatory offer and the subscription price of €4.10 per share for the capital increase that was carried out simultaneously helped to dispel speculations over a takeover battle.

Key share figures as of the end of the reporting period		**9M 2010**	**9M 2009**
Shares issued	Number	18,413,035	13,780,935
Market capitalisation	€ million	79.91	67.53
Closing price (XETRA)	€	4.34 (31.08.10)	4.90 (31.08.09)
High (all stock exchanges)	€	7.30 (21.06.10)	5.38 (14.07.09)
Low (all stock exchanges)	€	3.35 (09.03.10)	2.10 (22.12.08)
Volatility (260 days, XETRA)	%	68.2	73.62
Average daily trading volume (all stock exchanges)	Shares	48,403	13,955
Average daily trading volume (all stock exchanges)	€	214,377	50,201
Earnings per share	€	(1.06) [1]	(0.84)

[1] based on an average of 16,176,052 shares outstanding
Source: Bloomberg

The average daily trading volume of WILEX's shares in the first nine months of the financial year had more than tripled with 48,403 shares compared to 13,955 shares in the previous year. Especially in the third quarter, this development was heavily influenced by the capital measure and the mandatory offer. The Company's market capitalisation was about €85 million at the end of September.

Shareholder structure

The shareholder structure is as follows, given the capital measure and the mandatory offer by dievini Hopp BioTech:

Shareholder structure of WILEX AG



Financial calendar

Date	
22 February 2011	Annual Report 2010; Financial press conference and analysts' meeting
13 April 2011	3-month Financial Report 2011
18 May 2011	Annual General Meeting 2011
19 July 2011	Half-yearly Financial Report 2011
13 October 2011	9-month Financial Report 2011

Contact

WILEX AG
Grillparzerstr. 10
81675 Munich, Germany
Tel. + 49 (0) 89 – 41 31 38 – 0
Fax + 49 (0) 89 – 41 31 38 – 99
www.wilex.com
investors@wilex.com

Peter Llewellyn-Davies
Chief Financial Officer
Tel. + 49 (0) 89 – 41 31 38 – 20
Fax + 49 (0) 89 – 41 31 38 – 98
E-mail: pld@wilex.com

Katja Arnold (CIRO)
Senior Manager Corporate Communications
Tel. + 49 (0) 89 – 41 31 38 – 126
Fax + 49 (0) 89 – 41 31 38 – 99
E-mail: katja.arnold@wilex.com

Publishing information

Published by:	WILEX AG, Grillparzerstr. 10, 81675 Munich, Germany
Responsible for the project:	Katja Arnold, WILEX AG
Design by:	Annika Häussler, Artdirektion und Grafikdesign, Hamburg

The 9-month Financial Report is also published in German and is available for download from our website at www.wilex.com.

The English translation of the 9-month Financial Report is provided for convenience only. The German original is definitive.

As of: 12 October 2010

WILEX AG
Grillparzerstr. 10 · 81675 Munich · Germany · www.wilex.com